Rowley et al. 55F Glioblastoma with Recurrent Disease

by Benny | Apr 27, 2021

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 The ENHANCE Study Rowley et al. 55-year-old woman with glioblastoma with recurrent disease These are representative images...

Maravilla et al. 51F Metastatic Lung Cancer

by Benny | Apr 27, 2021

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Maravilla et al.51-year-old woman with metastatic lung cancer These are representative images from reference studies;...

Colosimo et al. 72F Primary Cerebral Lymphoma

by Benny | Apr 21, 2021

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Colosimo et al.72-year-old woman with primary cerebral lymphoma These are representative images from reference studies;...

Colosimo et al. 50M Metastatic Renal Carcinoma

by Benny | Apr 21, 2021

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Colosimo et al.50-year-old man with metastatic renal carcinoma These are representative images from reference studies;...

Colosimo et al. 52F Primary Glioma

by Benny | Apr 21, 2021

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Colosimo et al.52-year-old woman with primary glioma These are representative images from reference studies; individual...